Preoperative serum 8-hydroxydeoxyguanosine is associated with chemoresistance and is a powerful prognostic factor in endometrioid-type epithelial ovarian cancer

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Pylväs Eerola, Marjo ^a   Karihtala, Peeter ^a   Puistola, Ulla ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

8 OHdG; DJ 1; Endometrioid ovarian cancer; Epithelial ovarian cancer; Oxidative stress; Platinum resistance

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; DJ 1 PROTEIN; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; 8-OXO-7-HYDRODEOXYGUANOSINE; DEOXYGUANOSINE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CANCER CLASSIFICATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CLEAR CELL CARCINOMA; COLLOID CARCINOMA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENDOMETRIOID CARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GYNECOLOGIC SURGERY; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; OXIDATION REDUCTION STATE; PREOPERATIVE PERIOD; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; BLOOD; CARCINOMA, ENDOMETRIOID; DRUG RESISTANCE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OXIDATIVE STRESS; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, ENDOMETRIOID; DEOXYGUANOSINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OXIDATIVE STRESS; PROGNOSIS; YOUNG ADULT;

EID: 84934768455     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1504-6     Document Type: Article

References (43)

1. Murdoch WJ, Martinchick JF. Oxidative damage to DNA of ovarian surface epithelial cells affected by ovulation: carcinogenic implication and chemoprevention. Exp Biol Med. 2004;229:546-52.
2. Murdoch WJ. Carcinogenic potential of ovulatory genotoxity. Biol Reprod. 2005;73:586-90.
3. Murdoch WJ, Van Kirk EA, Alexander BM. Damages in ovarian surface epithelial cells of ovulatory hens. Exp Biol Med. 2005;230:429-33.
4. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999;91:1459-67.
5. Yang-Hartwich Y, Gurrea-Soteras M, Sumi N, Joo WD, Holmberg JC, Craveiro V, et al. Ovulation and extra-ovarian origin of ovarian cancer. Sci Rep. 2014; doi:10.1038/srep06116.
6. Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem. 2004;266:37-56.
7. Karihtala P, Soini Y, Vaskivuo L, Bloigu R, Puistola U. DNA adduct 8-hydroxydeoxyguanosine, a novel putative marker of prognostic significance in ovarian carcinoma. Int J Gynecol Cancer. 2009;19:1047-51.
8. Sova H, Jukkola-Vuorinen A, Puistola U, Kauppila S, Karihtala P. 8-Hydroxydeoxyguanosine: a new potential independent prognostic factor in breast cancer. Br J Cancer. 2010;102:1018-23.
9. Sheridan J, Wang LM, Tosetto M, Sheahan K, Hyland J, Fennelly D, et al. Nuclear oxidative damage correlates with poor survival in colorectal cancer. Br J Cancer. 2009;100:381-8.
10. Murtas D, Piras F, Minerba L, Ugalde J, Floris C, Maxia C, et al. Nuclear 8-hydroxy-2 -deoxyguanosine, a survival biomarker in patients with cutaneous melanoma. Oncol Rep. 2010;23:329-35.
11. Shen J, Deiniger P, Hunt JD, Zhao H. 8-Hydroxy-2 -deoxyguanosine (8-OH-dG) as a potential survival biomarker in patients with non-small-cell lung cancer. Cancer. 2007;109:574-80.
12. Peroja P, Pasanen AK, Haapasaari KM, Jantunen E, Soini Y, Turpeenniemi-Hujanen T, et al. Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B- cell lymphoma. Exp Hematol Oncol. 2012; doi:10.1186/2161-3619-1-2.
13. He H, Zhao Y, Wang N, Zhang L, Wang C. 8-Hydroxy-2 -deoxyguanosine expression predicts outcome of esophageal cancer. Ann Diagn Pathol. 2014;18:326-38.
14. Kondo S, Toyokuni S, Iwasa Y. Persistent oxidative stress in human colorectal carcinoma, but not in adenoma. Free Radic Biol Med. 1999;27:401-10.
15. Murawaki Y, Tsuchiya H, Kanbe T, Harada K, Yashima K, Nozaka K, et al. Aberrant expression of selenoproteins in the progression of colorectal cancer. Cancer Lett. 2008;259:218-30.
16. Junn E, Taniguchi H, Jeong BS, Zhao X, Ichijo H, Mouradian MM. Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. Proc Natl Acad Sci U S A. 2005;102:9691-6.
17. Kim RH, Peters M, Jang Y, Shi W, Pintilie M, Fletcher GC, et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell. 2005;7:263-73.
18. Bonifati V, Rizzu P, Squitieri F, Krieger E, Vanacore N, van Swieten JC, et al. DJ-1 (PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol Sci. 2003;24:159-60.
19. Merikallio H, Pääkkö P, Kinnula VL, Harju T, Soini Y. Nuclear factor erythroid-derived 2-like 2 (Nrf2) and DJ1 are prognostic factors in lung cancer. Hum Pathol. 2012;43:577-84.
20. Le Naour F, Misek DE, Krause MC, Deneux L, Giordano TJ, Scholl S, et al. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res. 2001;7:3328-35.
21. Zhu XL, Wang ZF, Lei WB, Zhuang HW, Jiang HY, Wen WP. DJ-1: a novel independent prognostic marker for survival in glottic squamous cell carcinoma. Cancer Sci. 2010;101:1320-5.
22. Yuen HF, Chan YP, Law S, Srivastava G, El-Tanani M, Mak TW, et al. DJ-1 could predict worse prognosis in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2008;17:3593-602.
23. Chen LL, Tian JJ, Su L, Jing Y, Zhang SC, Zhang HX, et al. DJ-1: a promising marker in metastatic uveal melanoma. J Cancer Res Clin Oncol. 2015;141:315-21.
24. Tsiaousidou A, Lambropoulou M, Chatzitheoklitos E, Tripsiais G, Tsompanidou C, Simopoulos C, et al. B7H4, HSP27 and DJ-1 molecular markers as prognostic factors in pancreatic cancer. Pancreatology. 2013;13:564-9.
25. Morelli M, Scumaci D, Di Cello A, Venturella R, Donato G, Faniello MC, et al. DJ-1 in endometrial cancer: a possible biomarker to improve differential diagnosis between subtypes. Int J Gynecol Cancer. 2014;24:649-58.
26. Pylväs M, Puistola U, Laatio L, Kauppila S, Karihtala P. Elevated serum 8-OHdG is associated with poor prognosis in epithelial ovarian cancer. Anticancer Res. 2011;21:1411-5.
27. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
28. Hirano T. Repair system of 7, 8-dihydro-8-oxoguanine as a defense line against carcinogenesis. J Radiat Res. 2008;49:329-40.
29. Cooke MS, Evans MD, Dove R, Rozalski R, Gackowski D, Siomek A, et al. DNA repair is responsible for the presence of oxidatively damaged DNA lesions in urine. Mutat Res. 2005;574:58-66.
30. Xu X, Wang Y, Guo W, Zhou Y, Lv C, Chen X, et al. The significance of the alteration of 8-OHdG in serous ovarian carcinoma. J Ovarian Res. 2013;doi:10.1186/1757-2215-6-74.
31. Valavanidis A, Viachogianni T, Fiotakis C. 8-Hydroxy-2-deoxyguanisine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Exotoxicol Rev. 2009;27:120-39.
32. Pylväs M, Puistola U, Kauppila S, Karihtala P. Oxidative stress-induced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis. Eur J Cancer. 2010;46:1661-7.
33. Sova H, Kangas J, Puistola U, Santala M, Liakka A, Karihtala P. Down-regulation of 8-hydroxyguanosine and peroxiredoxin II in the pathogenesis of endometriosis-associated ovarian cancer. Anticancer Res. 2012;32:3037-44.
34. Hayden A, Douglas J, Sommerland M, Andrews L, Gould K, Hussain S, et al. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer. Urol Oncol. 2014;32:806-14.
35. Gu L, Cui T, Fan C, Zhao H, Zhao C, Lu L, et al. Involvement of ERK1/2 signaling pathway in DJ-1-induced neuroprotection against oxidative stress. Biochem Biophys Res Commun. 2009;383:469-74.
36. Ismail IA, Kang HS, Lee HJ, Kwon BM, Hong SH. 2'-Benzoyloxycinnamaldehyde-mediated DJ-1 upregulation protects MCF-7 cells from mitochondrial damage. Biol Pharm Bull. 2012;35:895-902.
37. Inberg A, Linial M. Protection of pancreatic beta-cells from various stress conditions is mediated by DJ-1. J Biol Chem. 2010;285:25686-98.
38. Davidson B, Hadar R, Schlossberg A, Sternlicht T, Slipicevic A, Skrede M, et al. Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma. Hum Pathol. 2008;39:87-95.
39. Zhu ZM, Li ZR, Huang Y, Yu HH, Huang XS, Shao JH, et al. DJ-1 is involved in the peritoneal metastasis of gastric cancer through activation of the Akt signaling pathway. Oncol Rep. 2014;31:1489-97.
40. Kawate T, Iwaya K, Kikuchi R, Kaise H, Oda M, Sato E, et al. DJ-1 protein expression as a predictor of pathological complete remission after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2013;139:51-9.
41. Osman WM, Abd El Atti RM, Abou Gabal HH. DJ-1 and androgen receptor immunohistochemical expression in prostatic carcinoma: a possible role in carcinogenesis. J Egypt Natl Canc Inst. 2013;25:223-30.
42. Bai J, Guo C, Sun W, Li M, Meng X, Yu Y, et al. DJ-1 may contribute to metastasis of non-small cell lung cancer. Mol Biol Rep. 2012;39:2697-703.
43. Karihtala P, Mäenpää J, Turpeenniemi-Hujanen T, Puistola U. Front-line bevacizumab in serous epithelial ovarian cancer: biomarker analysis of the FINAVAST trial. Anticancer Res. 2010;30:1001-6.